Clinical Trials Logo
  1. Home
  2. Peritoneal Carcinomatosis
  3. NCT04950166

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Peritoneal Metastases in Patients Undergoing Cytoreductive Surgery

Peritoneal Carcinomatosis Clinical Trial

Official title:
A Phase 2, Single-Dose, Open-Label Study to Evaluate the Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Peritoneal Metastases, in Patients Undergoing Cytoreductive Surgery

Clinical Trial Summary

Peritoneal carcinomatosis (PC) results from the metastasis of a primary cancer of the peritoneum (e.g., appendiceal, ovarian, uterine, colorectal, and gastric cancers) that then disseminates throughout the abdominal cavity. Historically progression to PC was considered terminal and resulted in survival times on the scale of a few months with palliative care being the best option for patients. More recently, cytoreductive surgery (CS) has emerged as a means to prolong and improve patient lives with a median increase in survival of up to ~5 years. It has been reported that for every 10% increase in cytoreduction there is a 5.5% increase in median survival time. In addition to surgical tumor debulking within the peritoneal space, it has also been shown that coupling surgical intervention with hyperthermic intraperitoneal chemotherapy (HIPEC) can have an even greater impact on patient outcomes. Pegsitacianine, a micellar fluorescence agent, exploits the ubiquitous pH differences observed between cancerous and normal tissues. This in turn, provides a highly sensitive and specific fluorescence response after localizing within the tumor microenvironment, thus allowing the detection of primary tumors, their margins, metastatic disease, and tumor-containing lymph nodes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04950166
Study type Interventional
Source OncoNano Medicine, Inc.
Contact
Status Completed
Phase Phase 2
Start date November 30, 2021
Completion date January 20, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04826432 - Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis Phase 2
Recruiting NCT03127774 - Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Phase 2
Recruiting NCT04024917 - Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis N/A
Active, not recruiting NCT03508570 - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Phase 1
Not yet recruiting NCT04352894 - Intraoperative ICG Fluorescence Imaging for Peritoneal Carcinomatosis Detection N/A
Completed NCT05547568 - A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring?
Completed NCT06318793 - Preoperative Inflammatory Markers Predict Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Colorectal Carcinomatosis
Terminated NCT01683864 - Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer Phase 2/Phase 3
Recruiting NCT04547725 - Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis N/A
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Withdrawn NCT03682744 - CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) Phase 1
Terminated NCT04047771 - A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis Phase 1
Recruiting NCT05623787 - Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms N/A
Recruiting NCT05063019 - Role of Magnetic Resonance Enterography for Predicting Peritoneal Cancer Index N/A
Completed NCT02891447 - Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer Phase 2
Recruiting NCT04231175 - Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer N/A
Not yet recruiting NCT04734691 - Second Line Oxaliplatin Based Chemotherapy Alone Versus Oxaliplatin Based PIPAC and Chemotherapy in Colorectal Peritoneal Carcinomatosis : A Phase II Randomize Mutli-centric Study Phase 2
Recruiting NCT04108936 - Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses
Completed NCT02604784 - Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors Phase 1/Phase 2
Terminated NCT01540344 - Combined Anticancer Treatment of Advanced Colon Cancer Phase 2